行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.64倍，行业中值0.36倍。联合医 务市盈率8.41倍，行业排名第10位；其他巨星医疗控股（02393.HK）为0.33倍、京玖康疗（00648.HK） 为0.38倍、永胜医疗（01612.HK）为4.25倍、环球医疗（02666.HK）为4.64倍、瑞慈医疗（01526.HK） 为5.2倍。 资料显示，联合医务集团有限公司成立於1990年,为香港联交所主板上市公司(股份代号722.HK),是香港 及澳门领先的医疗保健平台,30年来一直致力让所有人获得可信任及可负担的服务,从而在不用担忧健康 的考虑下,追求自己的梦想。 联合医务除了为个人提供多元化的医疗保健服务,亦与企业及保险公司保持 紧密合作,为会员设计及管理企业医疗保健福利计划。近年来,联合医务更紧贴国家政策,於内地各主要城 市开展家庭医生培训服务,并与当地社区卫生服务机构携手打造公私营合作的联合医务诊室。 2020年度, 联合医务年就诊人次超过135万。目前联合医务旗下自设及联营的800多家医疗服务机构覆盖香港、澳 门、北京、天津、上海,以及粤港澳大湾区包括广州、深圳、珠海、中山、东莞 ...

Financial Performance - Revenue for the six months ended December 31, 2024, was HK$371,271,000, a decrease of 1.2% from HK$375,845,000 in the same period of 2023[11] - EBITDA increased by 17.0% to approximately HK$46,552,000 from HK$39,772,000 year-on-year[11] - Profit for the period rose by 45.7% to HK$19,246,000 compared to HK$13,209,000 in the previous year[11] - Profit attributable to owners of the Company increased by 14.6% to HK$17,948,000 from HK$15,668,000[11] - Basic and diluted earnings per share improved by 14.8% to 2.25 HK cents from 1.96 HK cents[11] - Total consolidated revenue decreased by 1.2% from HK$375.8 million in 1H FY23/24 to HK$371.3 million in 1H FY24/25[74] Cash and Assets - Cash, bank balances, and deposits increased by 18.4% to HK$303,259,000 from HK$256,139,000[11] - Net current assets rose by 6.0% to HK$231,769,000 compared to HK$218,719,000[11] - The Group's current assets increased to HK$532.97 million as of December 31, 2024, compared to HK$489.08 million as of June 30, 2024, while current liabilities rose to HK$301.20 million from HK$270.36 million[113] - The net current assets as of December 31, 2024, were HK$231.77 million, reflecting an increase from HK$218.72 million as of June 30, 2024[113] - Free cash and bank deposits amounted to approximately HK$301.2 million as of December 31, 2024, up from HK$253.3 million as of June 30, 2024[114] Operational Efficiency - Gross profit margin was maintained, reflecting improved operational efficiency[18] - Manpower costs improved by 4.4% year-on-year due to workforce optimization[18] - Rental expenses and depreciation of right-of-use assets decreased by approximately 15.0% year-on-year due to effective facility consolidations[18] - The company has implemented operational efficiency measures that resulted in a 4.4% reduction in human resources expenses year-on-year[21] - Professional services expenses decreased by 2.6% from HK$137.1 million to HK$133.5 million, attributed to increased operational efficiency[78] Revenue Segments - In the first half of FY24/25, total revenue for the Hong Kong & Macau Corporate Healthcare Solution Services segment increased by 4.1%, from HK$128.8 million in 1H FY23/24 to HK$134.1 million in 1H FY24/25[23] - Revenue from the Hong Kong & Macau Clinical Healthcare Services segment declined from HK$299.4 million in 1H FY23/24 to HK$289.2 million in 1H FY24/25, reflecting a decrease in patient visits and body check consumers[31] - Revenue from Mainland China segment increased from HK$19.3 million in 1H FY23/24 to HK$20.0 million in 1H FY24/25, reflecting a year-on-year growth of approximately 3.6%[37] - Revenue from corporate healthcare solution services increased by 4.1% to HK$134.1 million, while clinical healthcare services in Hong Kong decreased by 3.4% to HK$289.2 million[67] Strategic Initiatives - The company has established strategic partnerships and new service points in Mainland China, enhancing its network and service accessibility[24] - The company has diversified income sources by introducing new services such as Traditional Chinese Medicine (TCM) and physiotherapy to mitigate risks from declining immigration medical examination volumes[33] - The company won a government tender for nurse clinic services and allied health services, enhancing its service offerings in primary care[34] - The integration of artificial intelligence (AI) technology into medical imaging services is expected to improve diagnostic capabilities and patient care efficiency[34] - The company aims to expand its presence in the Greater Bay Area by partnering with local organizations to enhance outpatient care services[39] Future Outlook - The outlook for the second half of FY24/25 remains cautiously optimistic, with a focus on operational excellence and digital transformation to navigate global uncertainties[40] - Key priorities include improving cash flow generation and managing working capital effectively, with plans to streamline invoicing and payment collection processes[41] - Investment in a new patient management system is set to launch in the second half of FY24/25, aimed at enhancing patient data management and overall experience[49] - The company is focusing on preventive medicine and integrated care models to address rising healthcare costs and improve service delivery[54] Corporate Governance - The Audit Committee reviewed the unaudited interim results for the six months ended December 31, 2024, confirming compliance with relevant accounting standards and legal requirements[168] - The Company is committed to high standards of corporate governance and has confirmed compliance with the Corporate Governance Code during the reporting period[158] Shareholder Information - As of December 31, 2024, the total number of shares held by directors and the chief executive amounts to 389,346,659, representing approximately 48.01% of the issued shares[175] - The total number of issued shares as of December 31, 2024, is 810,955,244[177] - The Board declared an interim dividend of HKD 1.40 cents per ordinary share for the six months ended December 31, 2024, an increase from HKD 1.30 cents in the previous fiscal year[154]

Financial Performance - Revenue for the six months ended December 31, 2024, was HKD 371,271,000, a decrease of 1.2% compared to HKD 375,845,000 in 2023[3] - EBITDA increased by 17.0% to HKD 46,552,000 from HKD 39,772,000 year-over-year[3] - Net profit for the period rose by 45.7% to HKD 19,246,000, compared to HKD 13,209,000 in the previous year[3] - Basic and diluted earnings per share increased by 14.8% to HKD 2.25 from HKD 1.96[4] - Total comprehensive income for the period was HKD 13,822,000, significantly higher than HKD 2,345,000 in the previous year[5] - The pre-tax profit for the six months ended December 31, 2024, was HKD 22,629,000, compared to HKD 17,687,000 for the same period in 2023, reflecting a growth of 28.7%[23][26] - The net profit for the period was HKD 19,246,000, an increase of 45.5% from HKD 13,209,000 in the previous year[23][26] Dividends and Shareholder Returns - The company declared an interim dividend of HKD 1.40 per share, up 7.7% from HKD 1.30 in 2023[3] - The interim dividend proposed for the six months ended December 31, 2024, is HKD 1.40 per share, up from HKD 1.30 per share in the same period last year[35] - The board declared an interim dividend of HKD 1.40 per ordinary share for the six months ended December 31, 2024, compared to HKD 1.30 in the previous fiscal year[114] Assets and Liabilities - Cash, bank balances, and deposits increased by 18.4% to HKD 303,259,000 from HKD 256,139,000[3] - The net current assets increased by 6.0% to HKD 231,769,000 compared to HKD 218,719,000[3] - Trade receivables as of December 31, 2024, amounted to HKD 110,714,000, a decrease from HKD 131,025,000 as of June 30, 2024[42] - The total amount of trade payables as of December 31, 2024, was HKD 67,945,000, down from HKD 75,782,000 as of June 30, 2024[46] - Right-of-use assets increased to HKD 112.5 million as of December 31, 2024, from HKD 107.2 million as of June 30, 2024[90] - Lease liabilities amounted to HKD 125.7 million as of December 31, 2024, compared to HKD 120.7 million as of June 30, 2024[95] Operational Efficiency - The gross profit margin improved, with a gross profit margin of 12.5%, up 1.9 percentage points from 10.6%[3] - The company achieved a 4.4% reduction in human resources expenses year-on-year through optimized staffing[53] - Rental expenses and depreciation of right-of-use assets decreased by approximately 15.0% year-on-year due to effective facility integration[53] - Professional service fees decreased by 2.6% to HKD 133.5 million in the first half of FY2024/25 from HKD 137.1 million in the same period of FY2023/24, attributed to increased operational efficiency[79] - Employee benefit expenses reduced by 4.5% to HKD 96.1 million in the first half of FY2024/25, accounting for approximately 25.9% of total revenue[82] Market Segments - The external sales for the Hong Kong and Macau corporate healthcare solutions segment increased to HKD 133,160,000, up 4.4% from HKD 127,979,000 in the previous year[28] - The clinical healthcare services segment in Hong Kong and Macau reported external sales of HKD 218,108,000, a decrease of 4.6% from HKD 228,569,000 in the prior year[28] - Total revenue from corporate healthcare solutions in Hong Kong and Macau rose by 4.1% from HKD 128.8 million in the first half of 2023/24 to HKD 134.1 million in the first half of 2024/25[54] - Total revenue from clinical healthcare services in Hong Kong and Macau decreased from HKD 299.4 million in the first half of 2023/24 to HKD 289.2 million in the first half of 2024/25, a decline of 3.7%[58] - Revenue from clinical healthcare services in mainland China increased from HKD 19.3 million in the first half of FY2023/24 to HKD 20.0 million in the first half of FY2024/25, reflecting a year-on-year growth of 3.7%[61] Strategic Initiatives - The company continues to focus on expanding its healthcare services and enhancing its operational efficiency to drive future growth[19] - The company is expanding its network in mainland China by establishing strategic partnerships and new service points in key cities[56] - New services such as traditional Chinese medicine and physiotherapy have been introduced to diversify revenue sources and mitigate risks[60] - The company has begun implementing artificial intelligence technology in diagnostic services to enhance efficiency and accuracy in clinical environments[60] - The company is actively participating in public-private partnerships to enhance primary healthcare services, aligning with government initiatives[69] Financial Health and Compliance - The total tax expense for the period was HKD 3,383,000, a decrease of 24.5% from HKD 4,478,000 in the previous year[34] - The group has no bank borrowings or outstanding bank loans as of the announcement date[97] - The group continues to implement a conservative treasury policy to maintain a healthy liquidity position[96] - The group has no significant off-balance sheet arrangements as of December 31, 2024[105] - The company is committed to maintaining compliance with relevant accounting standards and regulations[120] Future Outlook - The company maintains a cautious optimism for the second half of FY2024/25 despite global uncertainties, leveraging its diversified revenue sources and strong operational foundation[62] - The company plans to invest in a new patient management system to enhance patient data management and overall patient experience, set to launch in the second half of FY2024/25[66] - The focus on digital transformation is a strategic cornerstone, with investments in AI technology for imaging and diagnostics to improve service quality and operational scalability[66] - The company aims to expand its presence in the Greater Bay Area by collaborating with local institutions to benefit from the increasing cross-border healthcare connections[61] Miscellaneous - The company operates three reportable segments: corporate healthcare solutions, clinical healthcare services in Hong Kong and Macau, and clinical healthcare services in mainland China[19] - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending December 31, 2024[122] - There have been no significant events from the end of the reporting period to the date of this announcement[123] - The interim results announcement will be published on the Hong Kong Stock Exchange website and the company's designated website[124] - The interim report for the six months ending December 31, 2024, will be sent to shareholders upon request and published on the relevant platforms[124] - The company has adopted a new share option plan approved on November 24, 2023[125] - The company operates a network of medical centers and affiliated clinics providing healthcare services[136] - The company is focused on expanding its services in the Greater Bay Area, which includes cities like Guangzhou and Shenzhen[130] - The company has a comprehensive range of medical services, including general and specialized medical care[136]

Financial Performance - For the fiscal year ended June 30, 2024, UMP reported a revenue of HK$748,489,000, representing an increase of 2.9% from HK$727,167,000 in the previous year[5]. - EBITDA decreased by 15.9% to HK$84,776,000 from HK$100,852,000 year-over-year[5]. - Profit for the year fell by 36.8% to HK$35,217,000 compared to HK$55,735,000 in the prior year[5]. - Profit attributable to owners of the company decreased by 32.8% to HK$40,643,000 from HK$60,452,000[5]. - Basic and diluted earnings per share dropped by 33.6% to HK$5.08 from HK$7.65[5]. - Proposed final dividend per share is HK$2.00, down 33.3% from HK$3.00 in the previous year[5]. - The net profit margin decreased to 11.3% from 13.9%, and return on shareholders' funds fell to 4.7% from 7.7%[5]. - Operating profit for FY2024 was HK$70,522,000, a decrease of 24.8% compared to HK$93,834,000 in FY2023[58]. - Total revenue for FY2024 reached HK$748,489,000, an increase of 2.9% from HK$727,167,000 in FY2023[57]. - Revenue from clinical healthcare services in Mainland China decreased by 3.5%, with operating profit declining by 18.3% due to post-pandemic market conditions[83]. Operational Developments - UMP's corporate solutions division saw increased utilization, leading to higher operational costs and pressure on profit margins[14]. - The company is expanding service offerings, including introducing Chinese medicine and collaborating with hospital groups for integrated care[15]. - UMP is focusing on partnerships with insurance companies and government agencies to implement effective health initiatives tailored to community needs[17]. - In FY2024, the company managed over 1.5 million patient visits across a network of over 1,300 clinics and service centers, serving more than 1.26 million scheme members[26]. - The utilization of the medical contract business increased significantly alongside a rise in contract membership, indicating a growing demand for comprehensive healthcare solutions[27]. - The company implemented strategies to safeguard profitability, including enhancing operational efficiency and streamlining processes to address rising operational expenses[28]. - Significant investments were made in medical imaging and laboratory testing facilities, which have enhanced overall income and profit[34]. - The introduction of Chinese Medicine services in Jordan expands the outpatient network and allows the company to explore new market segments[32]. - The company is adapting its service offerings in response to changes in client demand and economic conditions, focusing on client retention and service enhancement[63]. Market and Strategic Initiatives - The company is cautiously optimistic about growth prospects in Hong Kong, Macau, the Greater Bay Area, and Mainland China[47]. - Strategic partnerships with local governments and community stakeholders in Mainland China are aimed at establishing outpatient services[41]. - Collaboration with insurance firms has expanded cross-boundary services, allowing cashless transactions in Mainland China[42]. - The company is investing in cross-boundary medical services with approximately 20 service points in key mainland cities to meet rising demand[68]. - The focus on high-income consumer markets through UMP+ is expected to create additional revenue opportunities[43]. - The company emphasizes maintaining high standards and a positive reputation over merely increasing the number of locations in the competitive private healthcare market in China[86]. Employee and Workforce Management - The total number of employees decreased from 580 in FY2023 to 551 in FY2024, a reduction of approximately 5%[185]. - Employee turnover rate for FY2024 is reported at 49.87%, indicating a significant challenge in talent retention[187]. - The company emphasizes competitive remuneration and benefits to attract and retain talent[186]. - Internal promotions are encouraged to help employees realize their full potential[187]. - The Group strictly prohibits any form of forced labor and child labor, ensuring compliance with legal requirements during the recruitment process[197]. ESG and Community Engagement - The ESG Report highlights the Company's commitment to sustainable development, addressing significant enterprise risks that can impact returns[144]. - UMP Healthcare Holdings Limited is committed to sustainable innovation and actively supports 10 United Nations Sustainable Development Goals (SDGs) for a better future[151]. - The company aims to provide skills and knowledge to communities for thriving in a post-pandemic environment and transitioning to a sustainable future[172]. - The organization has received multiple awards, including "Caring Company 2023/2024" and "Outstanding Medical Group" by HK01, recognizing its commitment to social responsibility[160][161]. - The company collaborates with local organizations to promote community health and well-being through health education programs[153]. - UMP Healthcare aims to improve health outcomes and overall quality of life by providing accessible healthcare services to underserved populations[153].

Financial Performance - Revenue for the year ended June 30, 2024, was HKD 748,489,000, an increase of 2.9% from HKD 727,167,000 in 2023[1] - The profit before interest, tax, depreciation, and amortization (EBITDA) decreased by 15.9% to HKD 84,776,000 from HKD 100,852,000[1] - Net profit for the year was HKD 35,217,000, down 36.8% from HKD 55,735,000 in the previous year[1] - Basic and diluted earnings per share decreased by 33.6% to HKD 5.08 from HKD 7.65[1] - Proposed final dividend is HKD 2.00, a decrease of 33.3% from HKD 3.00 in the previous year[1] - The gross profit margin decreased to 11.3% from 13.9%, a decline of 2.6 percentage points[2] - The net profit margin also decreased to 4.7% from 7.7%, a decline of 3.0 percentage points[2] - The total comprehensive income for the year was HKD 14,004,000, significantly down from HKD 60,203,000 in the previous year[4] - Adjusted profit before tax for the year was HKD 40,624,000, compared to HKD 64,365,000 in the previous year, indicating a decrease of approximately 36.9%[17] - The company reported a net profit of HKD 35,217,000 for the year ended June 30, 2024, down from HKD 55,735,000 in the previous year, a decline of approximately 36.9%[17] Assets and Liabilities - Cash and bank balances decreased by 11.8% to HKD 256,139,000 from HKD 290,495,000[2] - Total equity decreased by 2.0% to HKD 725,942,000 from HKD 740,547,000[2] - Current liabilities totalled HKD 270,364,000 in 2024, a slight decrease of 0.3% from HKD 271,111,000 in 2023[6] - Net current assets decreased to HKD 218,719,000 in 2024 from HKD 224,413,000 in 2023, reflecting a decline of 2.5%[6] - Total non-current liabilities increased to HKD 91,781,000 in 2024, up 14.1% from HKD 80,424,000 in 2023[6] - Total liabilities for the company were HKD 392,557,000, compared to HKD 360,505,000 in the previous year, reflecting an increase of approximately 8.9%[16][18] Revenue Breakdown - The external sales breakdown included HKD 254,520,000 from Hong Kong and Macau corporate healthcare solutions, HKD 450,869,000 from clinical healthcare services in Hong Kong and Macau, and HKD 43,100,000 from clinical healthcare services in mainland China[15] - Revenue from healthcare solutions in Hong Kong and Macau was HKD 254,520,000, up from HKD 244,691,000, reflecting a growth of 4.0%[19] - Clinical healthcare services revenue reached HKD 450,869,000, compared to HKD 437,819,000 in the previous year, marking a growth of 3.0%[19] - Revenue from corporate healthcare solutions in Hong Kong and Macau reached HKD 255,840,000, up 3.9% from HKD 246,225,000[43] - Clinical healthcare services in Hong Kong and Macau generated HKD 583,084,000, an increase of 3.6% from HKD 562,774,000[43] Operational Highlights - The company operates primarily in healthcare services, including corporate healthcare solutions, medical and dental services, and medical imaging[7] - The company operates over 1,000 service points in Hong Kong and Macau as part of its UMP network[41] - The company has invested in and operates 10 advanced imaging and testing centers in Hong Kong as of June 30, 2024[42] - The company is expanding third-party management services in mainland China, aiming to attract local enterprises for cross-border healthcare[49] - The company established a strategic partnership with AXA Hong Kong to provide cross-border medical services, enhancing customer experience[48] Cost and Expenses - Employee benefit expenses rose to approximately HKD 197.0 million, an increase of about HKD 17.2 million or 9.6%, accounting for 26.3% of total revenue, compared to 24.7% in fiscal year 2023[60] - Professional service expenses increased by approximately HKD 15.5 million, or 6.1%, maintaining 36.2% of total revenue, up from 35.1% in fiscal year 2023[59] - Other expenses for fiscal year 2024 amounted to approximately HKD 81.6 million, an increase of about 10.3% from HKD 74 million in fiscal year 2023, primarily due to non-cash write-offs of other intangible assets[63] Strategic Initiatives - The company emphasizes sustainable growth and innovation in response to evolving market dynamics and consumer expectations[46] - The company is focusing on cost control measures and strategic marketing to address challenges in patient volume and profitability[50] - The establishment of the new Chinese medicine center is anticipated to significantly contribute to the overall growth of the group and strengthen its market position[54] - The company is strategically collaborating with local authorities to expand its presence in the Greater Bay Area, capitalizing on the growing demand for quality healthcare services[56] Governance and Compliance - The financial statements are prepared in accordance with Hong Kong Financial Reporting Standards, ensuring compliance with local regulations[8] - The company aims to maintain a high level of corporate governance and transparency, complying with the corporate governance code[89] - The audit committee consists of three independent non-executive directors with extensive experience in financial and corporate management[91] - The company has adopted a new share option scheme approved on November 24, 2023[97] Future Outlook - The company remains cautiously optimistic about growth prospects in Hong Kong, Macau, and mainland China, emphasizing the importance of strategic decision-making[57] - A new Chinese medicine center is set to begin operations in July 2024, expected to enhance service offerings and market position[54]

Share Option and Award Schemes - The company reported a total of 300,000 shares granted during the period under the Post-IPO Share Option Scheme[2]. - As of July 1, 2023, there were 1,500,000 options outstanding under the scheme, with 400,000 options granted during the period[15]. - The company adopted the 2023 Share Option Scheme on November 24, 2023, to replace the Post-IPO Share Option Scheme[20]. - Under the 2023 Share Option Scheme, the total number of shares that may be issued upon exercise of all options must not exceed 10% of the shares in issue as of the adoption date[21]. - As of December 31, 2023, no options were granted under the 2023 Share Option Scheme since its adoption[26]. - The number of options available for grant under the 2023 Share Option Scheme was 81,095,524 as of both November 24, 2023, and December 31, 2023[26]. - The Share Award Scheme, adopted on June 30, 2016, was amended to extend its term for another 10 years from the amendment date of November 24, 2023[29]. - The total number of shares available under the Service Provider Sublimit of the 2023 Share Option Scheme was 16,219,104 as of both November 24, 2023, and December 31, 2023[27]. - The company has a total of 25,740,000 options under the Post-IPO Share Option Scheme, with 14,140,000 options remaining as of December 31, 2023[19]. - The company aims to assist in the recruitment and retention of high-caliber professionals through the new share option schemes[20]. - The total number of shares available for the Share Award Scheme is 81,095,524 shares, representing approximately 10% of the issued shares as of the date of the interim report[33]. - 306,000 shares were purchased under the Share Award Scheme during the six months ended December 31, 2023, with a total amount paid of HK$210,245[33]. - As of December 31, 2023, 11,798,863 shares were held by the trustee of the Share Award Scheme for the benefit of eligible participants[33]. - The maximum number of shares that may be awarded to a selected participant under the Share Award Scheme in a 12-month period shall not exceed 1% of the issued share capital of the company[33]. - The board shall not make any further awards under the Share Award Scheme if the total number of awarded shares exceeds 10% of the shares in issue as of the amendment date[33]. - No share awards have been granted, vested, cancelled, or lapsed under the Share Award Scheme during the six months ended December 31, 2023[33]. Financial Performance - Revenue for the six months ended December 31, 2023, was HK$375,845,000, representing a 2% increase from HK$365,102,000 in the same period of 2022[49]. - Profit for the period decreased to HK$13,209,000, down 69% from HK$42,289,000 year-over-year[51]. - Basic and diluted earnings per share attributable to ordinary equity holders was HK1.96 cents, a decrease of 64% compared to HK5.43 cents in the previous year[49]. - Professional services expenses increased by 12% to HK$137,184,000 from HK$122,988,000 in the prior period[49]. - Employee benefit expenses rose to HK$100,597,000, up 11% from HK$90,202,000 year-over-year[49]. - Other comprehensive loss for the period was HK$10,864,000, compared to a comprehensive income of HK$7,123,000 in the previous year[51]. - The company reported a finance cost of HK$3,623,000, an increase from HK$2,966,000 in the prior period[49]. - Profit before tax for the six months ended December 31, 2023, was HK$17,687,000, a decrease of 64.6% compared to HK$49,920,000 for the same period in 2022[60]. - Cash generated from operations was HK$96,218,000, down 17.5% from HK$116,630,000 in the previous year[60]. - Net cash flows from operating activities amounted to HK$85,290,000, compared to HK$92,303,000 in the prior period, reflecting a decrease of 7.3%[60]. - The total tax charge for the period was HK$4,478,000, down from HK$7,631,000 in 2022, representing a decrease of about 41.5%[117]. - The effective tax rate remained consistent at 16.5% for both periods, reflecting stable tax policy adherence[101]. Dividends - The Board declared an interim dividend of HK1.30 cents per Share for the six months ended 31 December 2023, down from HK1.70 cents in the corresponding period in 2022[47]. - The interim dividend will be payable to shareholders on or about 19 April 2024, with the register of members closing from 20 March 2024 to 22 March 2024[47]. - The final dividend for the year ended 30 June 2023 is HK3.00 cents per ordinary share, unchanged from the previous year[123]. - The proposed interim dividend for the six months ending 31 December 2023 is HK1.30 cents per ordinary share, down from HK1.70 cents for the same period last year[125]. - The Group recognized a dividend distribution of HK$6,406,000 for the period ended December 31, 2023, compared to HK$11,579,000 in 2022, indicating a decrease of approximately 44.5%[122]. Assets and Liabilities - Total non-current assets as of December 31, 2023, were HK$624,856,000, slightly down from HK$625,730,000 as of June 30, 2023[53]. - Cash, bank balances, and deposits increased to HK$317,237,000 from HK$290,495,000, reflecting a 9% growth[53]. - Total current assets as of December 31, 2023, amounted to HK$523,862,000, up from HK$495,524,000 as of June 30, 2023[53]. - Total current liabilities increased to HK$317,505,000 as of December 31, 2023, compared to HK$271,111,000 on June 30, 2023, representing a 17.1% increase[55]. - Net current assets decreased to HK$206,357,000 as of December 31, 2023, down from HK$224,413,000 on June 30, 2023, indicating a decline of 8.0%[55]. - Total assets less current liabilities amounted to HK$831,213,000 as of December 31, 2023, compared to HK$850,143,000 on June 30, 2023, reflecting a decrease of 2.2%[55]. - Non-current liabilities rose to HK$87,471,000 as of December 31, 2023, up from HK$80,424,000 on June 30, 2023, marking an increase of 8.5%[55]. - Total equity decreased to HK$743,742,000 as of December 31, 2023, down from HK$769,719,000 on June 30, 2023, representing a decline of 3.4%[55]. - The reserves decreased to HK$720,218,000 as of December 31, 2023, compared to HK$739,736,000 on June 30, 2023, indicating a reduction of 2.6%[57]. Market and Business Strategy - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[56]. - The company has allocated resources for new technology research and development to enhance its service offerings[56]. - The Group continues to engage in various healthcare services, including corporate healthcare solutions and medical imaging, indicating ongoing market expansion efforts[64]. - The Group is focusing on strengthening interconnectivity within its service network to enhance patient-centric care and operational efficiency[150]. - The group plans to develop specialty medical facilities in oncology, cardiology, and orthopaedics to enhance service integration and cross-referrals[170]. - The establishment of strategic partnerships with reputable medical institutions is expected to increase revenue streams and improve overall profitability[172]. - The group aims to leverage the Voluntary Health Insurance Scheme (VHIS) to capture growing demand in the private healthcare market[170]. Segment Performance - The Corporate Healthcare Solution Services segment generated revenue of HK$127,979,000, slightly down from HK$128,371,000 in the previous year, indicating a decrease of about 0.3%[96]. - The Clinical Healthcare Services segment in Hong Kong and Macau reported revenue of HK$228,569,000, up from HK$217,962,000, reflecting an increase of approximately 4.9%[96]. - The Mainland China Clinical Healthcare Services segment achieved revenue of HK$19,297,000, compared to HK$18,769,000 in the prior year, marking a growth of about 2.8%[96]. - Revenue from clinical healthcare services in Hong Kong and Macau increased by 6.5% from HK$281.3 million in 2022/23 to HK$299.4 million in 2023/24, with approximately HK$90.1 million coming from medical imaging and laboratory services[166]. - Operating profit for Hong Kong and Macau clinical healthcare services decreased by 84.0% from HK$30.1 million in 2022/23 to HK$4.8 million in 2023/24, primarily due to increased service costs and expenses related to new medical centers[166]. - Revenue from clinical healthcare services in Mainland China rose by 2.8% from HK$18.8 million in 2022/23 to HK$19.3 million in 2023/24, with operating profit also increasing by 2.8% to HK$6.3 million[167]. Cash Flow and Financing - Cash flows from operating activities for the six months ended December 31, 2023, will be detailed in the upcoming cash flow statement[59]. - Net cash used in investing activities was HK$10,061,000, an increase from HK$8,031,000 in the same period last year[60]. - Principal portion of lease payments increased to HK$39,485,000 from HK$29,947,000, representing a rise of 31.5%[62]. - Net cash flows used in financing activities totaled HK$42,625,000, compared to HK$35,977,000 in the previous year, indicating an increase of 18.4%[62]. - Cash and cash equivalents at the end of the period were HK$269,937,000, down from HK$284,509,000 at the end of the previous period, a decrease of 5.1%[62]. - Interest received increased significantly to HK$2,775,000 from HK$579,000, marking a rise of 378.4%[60]. - The Group received HK$2,661,000 in dividends from a listed equity investment during the period, down from HK$5,002,000 for the same period in 2022[136]. Accounting and Reporting - The Group has adopted new accounting standards effective from July 1, 2023, which may impact future financial reporting[70]. - The Group's main business during the period is providing healthcare services, including medical and dental services[74]. - The unaudited condensed consolidated financial statements should be read in conjunction with the Group's annual consolidated financial statements for the year ended 30 June 2023[75]. - The adoption of HKFRS 17 is expected to have no material impact on the Group's total equity at 1 July 2023 and 1 July 2022[78]. - Amendments to HKAS 8 and HKAS 12 do not have a material impact on the financial statements, as the Group's approach is consistent with the amendments[79]. - The Group has revisited its accounting policy information and found it consistent with the recent amendments regarding material accounting policy disclosures[79]. - The Group's financial statements do not include all the information and disclosures required in the annual financial statements[75].

Financial Performance - The total comprehensive income for the six months ended December 31, 2023, was HKD 2,345,000, compared to HKD 49,412,000 for the same period in 2022, reflecting a significant decrease [4]. - The company's profit for the period was HKD 13,209,000, down from HKD 42,289,000 year-over-year [4]. - Revenue for the six months ended December 31, 2023, was HKD 375,845 thousand, a 2% increase from HKD 365,102 thousand for the same period in 2022 [46]. - The adjusted profit before tax for the group was HKD 49,920 thousand, compared to HKD 42,289 thousand for the same period in 2022, reflecting a significant increase [44]. - The company reported a decrease in profit attributable to equity holders from HKD 42.5 million in the 2022/23 interim period to HKD 15.7 million in the 2023/24 interim period, a decline of 63.1%, mainly due to increased service costs and depreciation expenses related to new imaging centers [94]. - The net profit for the period was HKD 13,209,000, a significant decrease of 68.8% compared to HKD 42,289,000 in the previous year [133]. - The basic and diluted earnings per share were HKD 1.96, down 63.9% from HKD 5.43 in the same period last year [132]. - The company's operating profit before interest, tax, depreciation, and amortization (EBITDA) was HKD 75,554,000, a decrease of 25.8% from HKD 101,820,000 in 2022 [132]. Assets and Liabilities - Non-current assets totaled HKD 624,856,000 as of December 31, 2023, slightly down from HKD 625,730,000 as of June 30, 2023 [6]. - Current assets increased to HKD 523,862,000 from HKD 495,524,000, indicating a growth of approximately 5.5% [6]. - The total liabilities increased to HKD 721,029,000 from HKD 740,547,000, showing a decrease of about 2.3% [7]. - The equity attributable to the owners of the company decreased to HKD 720,218,000 from HKD 739,736,000, reflecting a decline of about 2.8% [9]. - Trade receivables as of December 31, 2023, amounted to HKD 116.3 million, a slight decrease from HKD 121.1 million as of June 30, 2023 [81]. - The group had a net current asset value of HKD 206.4 million as of December 31, 2023, compared to HKD 224.4 million on June 30, 2023 [147]. - As of December 31, 2023, the group's right-of-use assets amounted to HKD 119.4 million, an increase from HKD 107.9 million as of June 30, 2023 [177]. Cash Flow and Investments - Cash and cash equivalents rose to HKD 317,237,000 from HKD 290,495,000, representing an increase of approximately 9.2% [6]. - The total cash, bank balances, and deposits as of December 31, 2023, were HKD 317,237,000, an increase of 9.2% from HKD 290,495,000 as of June 30, 2023 [132]. - The company has no significant interest rate risk as it has no bank borrowings or outstanding bank loans [136]. - The company confirmed compliance with the corporate governance code during the six months ended December 31, 2023 [182]. - The group did not engage in any significant acquisitions or disposals of subsidiaries during the 2023/24 interim period [161]. Revenue Sources - The company reported external sales of HKD 365,102 thousand, with the Hong Kong and Macau corporate healthcare solutions segment contributing HKD 128,371 thousand [44]. - Revenue for the clinical healthcare services (before inter-segment offsets) increased by 2.8% from HKD 18.8 million in the 2022/23 interim period to HKD 19.3 million in the 2023/24 interim period, with operating profit rising by 2.8% from HKD 6.1 million to HKD 6.3 million, attributed to improved operational efficiency and effective cost control [73]. - Revenue from clinical healthcare services in Hong Kong and Macau increased by 6.5% from HKD 281.3 million in 2022/23 to HKD 299.4 million in 2023/24, with approximately HKD 90.1 million coming from medical imaging and laboratory services [100]. - Revenue from mainland China clinical healthcare services grew by 11.6% from HKD 14.5 million in 2022/23 to HKD 16.2 million in 2023/24, indicating strong demand for quality healthcare [106]. Operational Efficiency - The company has completed a strategic expansion phase and is now concentrating on improving operational efficiency and financial performance [67]. - The company has merged several service points in the same region to reduce rent and operational expenses, thereby improving operational efficiency [96]. - The EBITDA for some newly opened centers reached breakeven during the 2023/24 interim period, indicating a positive trend in operational stability [72]. - The company is focusing on enhancing the interaction within its service network to create a patient-centered service experience [67]. Expenses and Costs - The total administrative expenses increased to HKD 209 thousand from HKD 189 thousand, indicating a rise in operational costs [31]. - Employee benefits expenses increased by 11.5% from HKD 90.2 million in the 2022/23 interim period to HKD 100.6 million in the 2023/24 interim period, primarily due to the expansion of the operational team related to two new medical and imaging centers launched in February and May 2023 [196]. - Cost of consumed inventory rose by 43.4% from HKD 20.0 million in the 2022/23 interim period to HKD 28.6 million in the 2023/24 interim period, mainly due to increased usage of pharmaceuticals and medical consumables related to oncology services [197]. - Depreciation and amortization increased by 14.5% from HKD 49.9 million in the 2022/23 interim period to HKD 57.1 million in the 2023/24 interim period, primarily related to capital expenditures from the previous fiscal year [198]. Future Outlook - The company maintains a long-term optimistic outlook despite operational challenges, anticipating strong demand for comprehensive medical services, advanced medical imaging, detailed health checks, and various auxiliary medical services due to increasing public health awareness and an aging population in Hong Kong [74]. - The company plans to strengthen specialty medical services, particularly in oncology, cardiology, and orthopedics, to enhance internal collaboration and resource efficiency [114]. - The company expects continued growth in the employee medical benefits and personal medical expenditure management market, driven by the government's voluntary health insurance scheme [103].

Financial Performance - Revenue from Hong Kong & Macau Clinical Healthcare Services increased by 12.5% from HK$500.4 million in FY2022 to HK$562.8 million in FY2023[22] - Operating profit for the clinical healthcare services decreased by 53.3% from HK$68.6 million in FY2022 to HK$32.0 million in FY2023[22] - Basic EPS for FY2023 was HK cents 7.65, reflecting a compound annual growth rate (CAGR) of 45.43% from FY2019 to FY2023[2] - Revenue from the Mainland China clinical healthcare business increased by 18.8% from HK$37.6 million in FY2022 to HK$44.7 million in FY2023, with operating profit rising 994.7% to HK$16.8 million[39] - For the fiscal year 2023, UMP's overall revenue increased year-over-year, driven by clinical services, despite short-term impacts from strategic investments in new imaging facilities[52] - Revenue from continuing operations increased by HK$61,308, or 9%, to HK$727,167,000 in 2023 compared to HK$665,859,000 in 2022[58] - EBITDA rose by HK$3,403, or 2%, to HK$170,533,000, up from HK$167,130,000[58] - Profit for the year decreased by HK$19,496, or 26%, to HK$55,735,000 from HK$75,231,000[58] - Profit attributable to owners from continuing operations fell by HK$10,050, or 14%, to HK$60,452,000 compared to HK$70,502,000[58] - The company reported a dividend per share of HK$3.2 for FY2023, reflecting a compound annual growth rate (CAGR) of 10.09% over the past five years[48] - Shareholders' equity reached HK$613 million in FY2023, with a CAGR of 4.84% from FY2019 to FY2023[49] Strategic Developments - New integrated imaging centre at 26 Nathan Road in Tsim Sha Tsui started operations in February 2023, providing various medical imaging services[23] - The company established strategic partnerships with several reputable medical groups to enhance service capabilities and expand service scope[22] - The company aims to be recognized as a one-stop comprehensive solution for corporate and insurance clients in healthcare[14] - The Group has entered into a service agreement with Humansa to provide dermatology and aesthetics services, enhancing strategic cooperation in the Greater Bay Area[35] - The Group is focusing on precision and preventive medicine, actively expanding advanced medical imaging and laboratory services in response to increasing demand[35] - A new one-stop multi-service medical centre is set to operate in Causeway Bay, offering various medical services including CT Scan and MRI[36] - The Innov Centre was established to showcase advanced medical technology and facilitate research and development projects, aiming to benefit the healthcare industry[30] - The company is focused on expanding its comprehensive healthcare services in response to increased cross-border activities post-pandemic[53] - UMP's corporate solutions division also saw increased operating profit during the fiscal year[52] - The company is committed to providing coordinated and holistic healthcare services as regional networks become more interconnected[53] Operational Efficiency and Growth - Significant initial operating expenses were recorded due to the opening of new medical and imaging centres[22] - The Group is optimistic about the growing demand for private imaging and laboratory services, expecting new imaging centres to drive revenue growth and business development[24] - The Group's financial performance is expected to improve with increased operational efficiency from new imaging centres[24] - The Group has committed to purchasing advanced medical imaging equipment to support the expansion of its services[35] - The company is focusing on integration efforts to optimize synergies and enhance customer experience through a digital transformation program[70] - The establishment of new healthcare facilities and services is anticipated to provide a solid platform for sustainable growth and long-term returns[118] Environmental and Social Responsibility - UMP's Scope 2 GHG emissions increased from 944.17 tonnes CO2e in FY2022 to 1,072.77 tonnes CO2e in FY2023, representing a rise of approximately 13.6%[128] - Emission intensity per visiting patient rose from 0.00086 tonnes CO2e in FY2022 to 0.00109 tonnes CO2e in FY2023, an increase of about 27%[128] - Medical waste produced surged from 2.48 tonnes in FY2022 to 6.36 tonnes in FY2023, marking a significant increase of 156.5%[128] - The Group recognizes the importance of good environmental stewardship and has implemented policies to ensure environmental protection[154] - The Group has a Code for the Disposal of Medical Waste in place, outlining its commitment to medical waste management[142] - The Group is committed to compliance with relevant laws and regulations regarding health and safety, advertising, labeling, and privacy matters[179] Governance and Compliance - The company has established a Nomination Committee responsible for reviewing the structure and diversity of the Board, ensuring alignment with corporate strategy[175] - The Board assessed the independence of directors and confirmed their ability to continue serving effectively, which supports governance standards[170] - The Group's business operations are subject to extensive laws, regulations, and licensing requirements, with compliance being critical to avoid harm to business and reputation[154] - The Group has adopted policies on minimizing its significant impact on the environment and natural resources[146] - The Group's success in Hong Kong significantly depends on the recognition of its brand and reputation as a leading corporate healthcare solutions provider[154]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 UMP HEALTHCARE HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） （股份代號：722） 截至2023年6月30日止年度之 年度業績公告 財務摘要 截至6月30日止年度╱ 於6月30日 2023年 2022年 增加╱（減少） (A) 經營業績（千港元） 持續經營業務： 收入 727,167 665,859 61,308 9% 未計利息、稅項、折舊及攤銷 前的利潤（附註a） 170,533 167,130 3,403 2% 年內利潤 55,735 75,231 (19,496) (26%) ...

Financial Performance - Revenue for the six months ended December 31, 2022, was HK$365,102,000, representing a 2% increase from HK$358,210,000 in 2021[12]. - EBITDA for the same period was HK$101,820,000, reflecting a 3% increase from HK$98,615,000 in 2021[12]. - Profit attributable to owners from continuing operations decreased by 5% to HK$42,469,000 compared to HK$44,661,000 in the previous year[12]. - Total profit decreased by 8% to HK$42,469,000 from HK$46,327,000 in 2021[12]. - Basic and diluted earnings per share decreased by 10% to 5.425 HK cents from 6.053 HK cents[12]. - Total consolidated revenue from continuing operations increased by 1.9% from HK$358.2 million in 1HFY2022 to HK$365.1 million in 1HFY2023[110]. - For the six months ended December 31, 2022, total revenue decreased by 10.6% to HK$576.4 million compared to HK$645.0 million in the same period of 2021[136]. Dividends and Shareholder Returns - Interim dividend per share increased by 13% to 1.70 HK cents from 1.50 HK cents[12]. - The Board declared an interim dividend of HK1.70 cents per ordinary share for the six months ended 31 December 2022, an increase from HK1.50 cents in FY2022[193]. Cash and Assets - Cash and pledged deposits increased by 20% to HK$286,902,000 from HK$238,120,000[12]. - As of December 31, 2022, the Group had cash and cash equivalents of HK$284.5 million and no bank borrowings or outstanding loans[151]. - The Group's gearing ratio was zero as of December 31, 2022, indicating no net debt[153]. - As of December 31, 2022, the Group's right-of-use assets amounted to HK$137.1 million, a slight increase from HK$136.0 million as of June 30, 2022[138]. - Investments at fair value through other comprehensive income increased to HK$37.5 million, while financial assets at amortised cost decreased to HK$6.3 million as of December 31, 2022[144]. Operational Developments - The company launched its first personalized healthcare scheme in October 2022, enhancing its corporate healthcare solutions[20]. - Two new imaging centers equipped with advanced technology such as PET-CT and MRI are set to begin operations this year[19]. - The company established a new large medical ecosystem in Central, enhancing one-stop healthcare services for patients[22]. - The UMP Healthcare Innov Centre was established to showcase advanced medical application technologies and explore AI in diagnosis and care processes[25]. - The Group's extensive clinical chains support both corporate healthcare solutions and walk-in users, with demand for specialist services remaining stable despite pandemic impacts[60]. Market and Strategic Initiatives - The company aims to create a sustainable healthcare system that is accessible, inclusive, and affordable while ensuring profitability[31]. - The company remains cautiously optimistic about market recovery as cross-border travel resumes, serving the region's 80 million citizens[29]. - Strategic collaborations with private hospitals and healthcare groups are being pursued to enhance service delivery and operational efficiency[30]. - The demand for body health check services continued to rise due to increased healthcare awareness and an aging population[64]. - The Group aims to consolidate strengths and increase overall market share and competitiveness in the healthcare sector[96]. Employee and Operational Costs - Employee benefit expenses increased by 7.5% from HK$83.9 million in 1HFY2022 to HK$90.2 million in 1HFY2023, aligning with the company's talent strategy for business growth[123]. - Professional services expenses decreased by 3.4% from HK$127.3 million in 1HFY2022 to HK$123.0 million in 1HFY2023, reflecting a reduction in service costs from healthcare professionals[121]. - Initial operating expenses from new integrated services medical centres at OCC contributed to the decline in operating profit for clinical healthcare services[59]. Governance and Leadership - Dr. SUN Yiu Kwong retired as CEO effective January 1, 2023, while remaining as Chairman and an executive Director[199]. - The Company has complied with the Corporate Governance Code by separating the roles of Chairman and CEO[199]. - The Board will periodically review the corporate governance structure and practices[200].